Key result
Lower and less frequent dosing of lepirudin, guided by aPTT results, is recommended for patients with dialysis-dependent renal failure due to considerable variability in patient response.
Why the study?
Does lower and less frequent lepirudin dosing prevent overanticoagulation in patients with dialysis-dependent renal failure and heparin-induced thrombocytopenia?
Does lower and less frequent lepirudin dosing prevent overanticoagulation in patients with dialysis-dependent renal failure and heparin-induced thrombocytopenia?
In patients with dialysis-dependent renal failure, lepirudin should be administered at lower and less frequent doses than currently recommended, guided by aPTT, to avoid severe overanticoagulation.
Answers are grounded in this paper and cite their sources.
Supports aPTT-guided lower lepirudin dosing in dialysis patients; leaves open prospective validation of regimens and outcomes.
Lepirudin is a direct thrombin inhibitor indicated for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. In patients with normal renal function, a bolus dose of 0.4 mg/kg is injected over 15-20 seconds, followed by a continuous infusion of 0.15 mg/kg/hour adjusted to prolong the activated partial thromboplastin time (aPTT) to 1.5-2.5 times the patient's baseline. Because renal function directly influences lepirudin elimination, patients with renal impairment require significant adjustments in the initial infusion rate. Current recommendations suggest that patients with dialysis-dependent renal failure should receive an initial bolus of 0.2 mg/kg, followed by 0.1 mg/kg every other day if the aPTT falls below the lower limit of the therapeutic range; however, this dosing may result in significant and prolonged overanticoagulation. A review of available literature regarding pharmacokinetics of lepirudin in renal failure suggests considerable variability in patient response over a narrow creatinine clearance range. Because there is no antidote for lepirudin if significant bleeding occurs, lower and less frequent dosing, guided by aPTT results, is recommended.
No takes yet. Share an insight, caveat, or question.
Wittkowsky et al. (2000) conducted a review in Heparin-induced thrombocytopenia with dialysis-dependent renal failure. Lepirudin was evaluated. Lower and less frequent dosing of lepirudin, guided by aPTT results, is recommended for patients with dialysis-dependent renal failure due to considerable variability in patient response.
Synapse has enriched 10 related papers. Consider them for comparative context: